PMID- 27655682
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 48
DP  - 2016 Nov 29
TI  - A rational approach for cancer stem-like cell isolation and characterization 
      using CD44 and prominin-1(CD133) as selection markers.
PG  - 78499-78515
LID - 10.18632/oncotarget.12100 [doi]
AB  - The availability of adequate cancer stem cells or cancer stem-like cell (CSC) is 
      important in cancer study. From ovarian cancer cell lines, SKOV3 and OVCAR3, we 
      induced peritoneal ascites tumors in immunodeficient mice. Among the cells 
      (SKOV3.PX1 and OVCAR3.PX1) from those tumors, we sorted both CD44 and CD133 
      positive cells (SKOV3.PX1_133+44+, OVCAR3.PX1_133+44+), which manifest the 
      characteristics of self-renewal, multi-lineage differentiation, chemoresistance 
      and tumorigenicity, those of cancer stem-like cells (CSLC). Intraperitoneal 
      transplantation of these CD44 and CD133 positive cells resulted in poorer 
      survival in the engrafted animals. Clinically, increased CD133 expression was 
      found in moderately and poorly differentiated (grade II and III) ovarian serous 
      cystadenocarcinomas. The ascites tumor cells from human ovarian cancers 
      demonstrated more CD133 and CD44 expressions than those from primary ovarian or 
      metastatic tumors and confer tumorigenicity in immunodeficient mice. Compared to 
      their parental cells, the SKOV3.PX1_133+44+ and OVCAR3.PX1_133+44+ cells uniquely 
      expressed 5 CD markers (CD97, CD104, CD107a, CD121a, and CD125). Among these 
      markers, CD97, CD104, CD107a, and CD121a are significantly more expressed in the 
      CD133+ and CD44+ double positive cells of human ovarian ascites tumor cells 
      (Ascites_133+44+) than those from primary ovarian or metastatic tumors. The 
      cancer stem-like cells were enriched from 3% to more than 70% after this 
      manipulation. This intraperitoneal enrichment of cancer stem-like cells, from 
      ovarian cancer cell lines or primary ovarian tumor, potentially provides an 
      adequate amount of ovarian cancer stem-like cells for the ovarian cancer study 
      and possibly benefits cancer therapy.
FAU - Lee, Yi-Jen
AU  - Lee YJ
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 
      Taiwan.
FAU - Wu, Chang-Cheng
AU  - Wu CC
AD  - Chief of Obstetrics and Gynecology, Tri-Service General Hospital Penghu Branch, 
      Penghu, Taiwan.
FAU - Li, Jhy-Wei
AU  - Li JW
AD  - Chief of Pathology, Da-Chien General Hospital, Miaoli, Taiwan.
AD  - Department of Rehabilitation science, Jente Junior College of Medicine, Nursing 
      and Management, Miaoli, Taiwan.
FAU - Ou, Chien-Chih
AU  - Ou CC
AD  - Obstetrics and Gynecology, Tri-Service General Hospital, Taipei, Taiwan.
FAU - Hsu, Shih-Chung
AU  - Hsu SC
AD  - Medical Care and Management, Kang-Ning Junior College, Taipei, Taiwan.
FAU - Tseng, Hsiu-Hsueh
AU  - Tseng HH
AD  - Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, 
      Taiwan.
FAU - Kao, Ming-Ching
AU  - Kao MC
AD  - Department of Biological Science and Technology, China Medical University, 
      Taichung, Taiwan.
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan.
FAU - Liu, Jah-Yao
AU  - Liu JY
AD  - Department of Obstetrics and Gynecology, National Defense Medical Center, Taipei, 
      Taiwan.
AD  - Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (AC133 Antigen)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (PROM1 protein, human)
SB  - IM
MH  - AC133 Antigen/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Ascitic Fluid/*metabolism/pathology
MH  - Biomarkers, Tumor/*metabolism
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Cell Lineage
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cell Self Renewal
MH  - Cell Separation/*methods
MH  - Cystadenocarcinoma, Serous/drug therapy/genetics/*metabolism/secondary
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - *Flow Cytometry
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - Mice, Inbred NOD
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Neoplasm Metastasis
MH  - Neoplastic Stem Cells/drug effects/*metabolism/pathology
MH  - Ovarian Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Phenotype
MH  - Time Factors
MH  - Tumor Burden
MH  - Tumor Cells, Cultured
PMC - PMC5346656
OTO - NOTNLM
OT  - CD44 and CD133
OT  - OVCAR3.PX1_133+44+
OT  - SKOV3.PX1_133+44+
OT  - cancer stem-like cells (CSLC)
OT  - intraperitoneal enrichment
COIS- CONFLICTS OF INTEREST The authors report that there is no conflicts of interest.
EDAT- 2016/09/23 06:00
MHDA- 2018/02/21 06:00
PMCR- 2016/11/29
CRDT- 2016/09/23 06:00
PHST- 2015/04/13 00:00 [received]
PHST- 2016/09/12 00:00 [accepted]
PHST- 2016/09/23 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2016/09/23 06:00 [entrez]
PHST- 2016/11/29 00:00 [pmc-release]
AID - 12100 [pii]
AID - 10.18632/oncotarget.12100 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Nov 29;7(48):78499-78515. doi: 10.18632/oncotarget.12100.